This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 7-10, 2023 | In-Person + Digital
San Diego, CA, USAManchester Grand Hyatt San Diego

Aimee Jackson, PhD
Chief Scientific Officer at Atalanta Therapeutics


Aimee Jackson, PhD, Chief Scientific Officer, Atalanta Therapeutics Aimee has worked in the field of RNA interference and oligonucleotide therapeutics for >20 years. Aimee most recently served as the Vice President of Research for miRagen Therapeutics, where she advanced 3 microRNA programs from initial concept to First-in-Human clinical trials in less than 5 years. These programs encompassed diverse therapeutic areas and comprised both microRNA mimics and inhibitors. All three programs successfully completed Phase 1 clinical trials, and two of these programs have advanced to Phase 2 clinical trials, including a fibrosis program for which Aimee served as the Product Development Team Lead. Prior to joining miRagen, she led preclinical research at Regulus Therapeutics and Merck/Rosetta, where she served as Molecular Profiling Lead for the development of siRNA-based therapeutics. Known for identifying siRNA off-target effects, she played a lead role in the identification of siRNA design and chemistry aspects for enhanced activity and specificity.

Aimee is known for being passionate about cutting-edge and innovative approaches to technology and medicine to improve patients’ lives.

Agenda Sessions

  • A Novel Approach to Improved Distribution, Durability, and Potency of RNAi across the CNS